Last updated: August 28, 2026
Accrufer, Shield Therapeutics’ oral ferric maltol product, is moving from commercial launch to scale-up in the U.S. iron-deficiency anemia market. Revenue growth has been driven by wider payer access, primary-care prescribing, and conversion from poorly tolerated conventional oral iron. The principal commercial risks are high patient-acquisition costs, dependence on U.S. reimbursement, competition from low-cost generic ferrous salts and intravenous iron, and Shield’s financing requirements while the product expands.
What is Accrufer and which company markets it?
Accrufer is the U.S. brand name for ferric maltol, an oral iron replacement therapy approved for the treatment of iron deficiency in adults. Shield Therapeutics owns the U.S. commercial rights and markets the product through its U.S. subsidiary, Shield Therapeutics Inc. [1]
| Item |
Accrufer profile |
| Active ingredient |
Ferric maltol |
| Brand name outside the U.S. |
Feraccru |
| Dosage form |
30 mg oral capsule |
| U.S. indication |
Treatment of iron deficiency in adults |
| U.S. approval |
July 25, 2021 |
| U.S. commercial launch |
2022 |
| U.S. rights holder |
Shield Therapeutics |
| European commercialization |
Primarily licensed to Norgine |
| Therapeutic category |
Oral iron replacement |
| Key alternatives |
Ferrous sulfate, ferrous fumarate, ferrous gluconate, ferric carboxymaltose, iron sucrose, ferumoxytol |
The product is positioned for adults who need oral iron but cannot tolerate conventional ferrous salts or do not achieve adequate repletion. Its commercial differentiation is based on tolerability and absorption rather than a fundamentally new treatment pathway.
How large is the Accruer market opportunity?
The addressable market is broad, but the commercially reachable segment is narrower. Iron deficiency affects patients with inflammatory bowel disease, chronic kidney disease, heart failure, gynecologic blood loss, gastrointestinal disorders, and other chronic conditions. Many patients receive inexpensive generic oral iron first, while patients with severe deficiency, intolerance, poor adherence, or inadequate response may move to intravenous iron.
Accruer’s practical target market has four segments:
- Adults who discontinue generic oral iron because of gastrointestinal adverse effects.
- Patients with inflammatory or gastrointestinal conditions who need an oral product with a differentiated tolerability profile.
- Patients who have not responded adequately to conventional oral iron.
- Patients for whom physicians want to delay or avoid intravenous iron.
The market structure limits pricing power. Generic ferrous sulfate is widely available at a small fraction of Accruer’s branded cost. Intravenous iron is more expensive but has stronger reimbursement support in several specialty settings and bypasses gastrointestinal absorption.
How does Accruer compare with competing iron products?
| Product category |
Main advantage |
Main limitation |
Competitive effect on Accruer |
| Generic ferrous sulfate and related salts |
Very low cost and broad familiarity |
Gastrointestinal intolerance and adherence problems |
Largest first-line barrier |
| Accruer ferric maltol |
Oral administration and differentiated tolerability |
Branded price and slower market adoption |
Direct branded opportunity |
| Ferric carboxymaltose |
Rapid intravenous repletion |
Infusion burden, cost, hypophosphatemia risk |
Strong substitute for severe deficiency |
| Iron sucrose |
Established hospital and dialysis use |
Requires infusion administration |
Limits specialty-market penetration |
| Ferumoxytol |
Intravenous dosing with relatively short treatment courses |
Infusion setting and safety monitoring |
Competes in patients needing rapid repletion |
| Oral ferric citrate |
Iron delivery with additional phosphate-binding use in kidney disease |
Different primary treatment profile |
Relevant in chronic kidney disease |
Accruer is therefore a “step-up oral” product. Its growth depends on identifying patients who are poorly served by generic oral iron before they are directed to intravenous therapy.
What has driven Accruer’s revenue growth?
Shield’s commercial trajectory has been characterized by rapid percentage growth from a small base. The company reported approximately $21.7 million in total revenue for 2022 and approximately $65.6 million for 2023, representing roughly 200% growth year over year on the company’s reported basis. [2,3]
| Fiscal period |
Reported revenue |
Commercial interpretation |
| 2021 |
Pre-U.S.-launch base |
U.S. product approval; limited commercial contribution |
| 2022 |
Approximately $21.7 million |
Initial U.S. launch and early prescription expansion |
| 2023 |
Approximately $65.6 million |
Broader payer access, higher prescription volume, and sales-force expansion |
| 2024 |
Growth phase |
Continued U.S. penetration, with profitability dependent on sales and marketing efficiency |
The exact contribution of U.S. Accruer sales differs from consolidated revenue because Shield also receives revenue from European operations and licensing arrangements. The central financial driver, however, has been U.S. Accruer prescription growth.
The product’s revenue model has several favorable characteristics:
- Repeat use can extend beyond a single short treatment course.
- Oral administration allows prescribing in primary care and specialty clinics.
- Payer coverage can expand the eligible patient pool.
- The company can use specialty-pharmacy and hub services to improve fulfillment and persistence.
- Manufacturing is less complex than for an injectable biologic or sterile intravenous product.
The cost structure is less favorable during the build-out period. Shield must fund field sales, patient support, payer contracting, sampling, medical education, and working capital before prescription volume reaches mature levels.
When does Accruer lose exclusivity?
Accruer does not face biosimilar risk because ferric maltol is a small-molecule drug, not a biologic. The principal future threat is generic ferric maltol or an abbreviated new drug application, together with substitution by existing generic oral iron and intravenous products.
U.S. exclusivity has two separate components:
| Protection |
Status |
| FDA regulatory exclusivity |
New Chemical Entity exclusivity expired in 2026, based on the July 2021 approval date |
| Patent protection |
Depends on the specific Orange Book-listed patents, pediatric extensions, patent-term adjustment, and any litigation outcomes |
| Generic pathway |
ANDA applicants may challenge listed patents through Paragraph IV certifications |
| Biosimilar pathway |
Not applicable |
The FDA’s five-year new chemical entity exclusivity period prevents approval of an ANDA relying on Accruer’s approval during the statutory exclusivity term, subject to applicable filing rules. That period does not prevent a full 505(b)(2) application or independent development pathway in every circumstance. [4]
A generic launch date cannot be inferred from regulatory exclusivity alone. It depends on the Orange Book patent list, the expiration dates of relevant claims, any Paragraph IV notice, litigation, settlement terms, and possible 180-day first-filer exclusivity.
What patents protect Accruer?
The Accruer patent estate is centered on ferric maltol compositions, oral formulations, and therapeutic use. The commercial value of these patents depends on whether a generic applicant can design around the claims or invalidate them.
Relevant protection categories include:
Composition and formulation patents
These claims can cover ferric maltol itself, specified solid forms, pharmaceutical compositions, capsule formulations, and dosage ranges. Formulation claims may be particularly important if the approved product relies on a defined ferric maltol composition or release profile.
Method-of-use patents
Use claims may cover treatment of iron deficiency, iron-deficiency anemia, or patient populations that cannot tolerate conventional iron salts. Method-of-use patents are vulnerable to “skinny label” strategies if a generic applicant omits patented indications from its labeling.
Manufacturing and process protection
Manufacturing claims can cover preparation of ferric maltol, control of impurities, particle characteristics, or conversion into the finished capsule. These patents are harder to assess from public commercial data because infringement may occur inside an undisclosed manufacturing process.
Orange Book and Paragraph IV exposure
The key legal issue is whether Shield has an enforceable patent remaining after the NCE exclusivity period. An ANDA applicant that certifies a listed patent is invalid, unenforceable, or not infringed can trigger a Paragraph IV notice and, if Shield sues within 45 days, a statutory stay of FDA approval for up to 30 months. [5]
Publicly reported commercial materials identify intellectual-property protection as a component of Accruer’s long-term value, but the precise generic-entry date must be tied to the current FDA Orange Book listing rather than to the product’s approval date alone. No confirmed Accruer Paragraph IV litigation or generic settlement is incorporated into the revenue assumptions above.
What is the FDA regulatory status of Accruer?
The FDA approved Accruer under a 505(b)(2) pathway on July 25, 2021. The approved labeling covers treatment of iron deficiency in adults. [1]
The regulatory status supports continued commercialization, but it does not eliminate market-access constraints. Accruer must compete within pharmacy benefit designs that often require generic iron before branded oral products. Prior authorization, step therapy, formulary exclusions, and specialty-pharmacy requirements can reduce prescription conversion.
The product’s regulatory profile is commercially favorable in one respect: it is an oral small-molecule capsule, so it does not require infusion-center infrastructure. That advantage is offset by the difficulty of persuading payers to reimburse a branded oral therapy when several low-cost alternatives exist.
Which companies are challenging Accruer commercially?
No single competitor has to duplicate ferric maltol to pressure Accruer. The competitive field includes generic manufacturers, branded intravenous-iron companies, and companies selling oral iron products.
Generic oral-iron manufacturers
Manufacturers of ferrous sulfate, ferrous fumarate, and ferrous gluconate remain the largest competitive group. Their low acquisition cost makes them the default treatment for many primary-care patients.
Intravenous-iron companies
Vifor Pharma, CSL Vifor, Pharmacosmos, and other manufacturers compete for patients who need rapid repletion or have failed oral therapy. Their products include Injectafer, Monoferric, Venofer, and Feraheme, depending on market and indication.
Contract and specialty-pharmacy channels
Accruer’s commercial competition also occurs at the channel level. Pharmacy benefit managers, specialty pharmacies, wholesalers, and integrated health systems influence prescribing and net price. A product can gain prescriptions while producing weaker revenue growth if rebates and patient-support discounts rise.
How strong is the Accruer patent and commercial estate?
Accruer has moderate commercial differentiation but a less secure economic moat than an injectable biologic or a product with a long period of unchallenged composition-patent protection.
The strongest assets are:
- An FDA-approved branded product with clinical and prescribing history.
- A differentiated oral ferric-maltol mechanism relative to ferrous salts.
- A potentially better-tolerated profile for selected patients.
- Existing European experience with Feraccru.
- A commercial platform focused on iron deficiency and anemia.
The principal weaknesses are:
- Low-cost generic oral alternatives.
- Limited switching friction for prescribers.
- Intravenous products that can produce faster iron repletion.
- Dependence on payer coverage.
- Uncertainty around post-exclusivity generic timing.
- High sales and marketing costs relative to current scale.
- Financing exposure while the company funds commercial expansion.
The patent estate should be treated as a time-limited support for pricing, not as a permanent barrier to substitution.
What generic launch scenarios exist for Accruer?
Scenario 1: No immediate generic launch
Shield retains effective patent protection after NCE exclusivity, and no ANDA applicant obtains approval quickly. Revenue can continue growing as payer access and physician awareness improve.
Scenario 2: Authorized or limited generic competition
A settlement or licensing arrangement permits a generic launch before the final patent expiry. Net pricing declines, but Shield may retain a portion of branded demand.
Scenario 3: First-filer Paragraph IV launch
A successful Paragraph IV challenger could enter before the nominal patent expiry, depending on litigation results and 180-day exclusivity. This would create the sharpest price and volume risk.
Scenario 4: Therapeutic substitution without ferric-maltol generic entry
Even without a generic Accruer, physicians may shift patients to generic ferrous salts or intravenous iron. This scenario can weaken revenue before formal patent expiry.
What licensing deals affect Accruer?
Shield licensed ferric maltol commercialization rights in Europe to Norgine, which markets the product as Feraccru. The European arrangement gives Shield access to regional commercialization capabilities while reducing the need to build a full direct infrastructure in every market. [6]
The U.S. business has greater revenue upside because Shield controls the commercial launch, but it also carries greater operating costs. The European model is more royalty- and milestone-oriented, while the U.S. model is more directly exposed to prescription volume, gross-to-net deductions, and sales-force productivity.
What litigation and settlement risks affect Accruer?
The principal legal risk is future ANDA litigation rather than a currently established biosimilar dispute. Important events to monitor include:
- New Orange Book patent listings.
- Paragraph IV notices.
- District-court complaints filed within 45 days of notice.
- A 30-month stay of ANDA approval.
- Claim-construction and invalidity rulings.
- Inter partes review petitions.
- Generic settlement or license agreements.
- Any authorized-generic strategy.
- Patent-term-adjustment changes.
A settlement could protect near-term revenue while shortening the period of branded exclusivity. Its financial effect would depend on the agreed launch date, royalty rate, market-share restrictions, and whether multiple generic entrants receive access.
What is the financial outlook for Accruer?
Accruer’s financial trajectory depends on whether prescription growth outpaces the costs of market development. The product can become economically attractive at scale because manufacturing costs for an oral capsule are generally lower than those for sterile injectable products. The business still requires substantial investment in commercial infrastructure.
The main financial indicators are:
| Indicator |
Directional implication |
| New prescriptions |
Measures physician adoption |
| Total prescriptions |
Measures persistence and repeat treatment |
| Gross-to-net discount |
Determines realized price |
| Payer coverage |
Expands or restricts access |
| Cost per acquired patient |
Determines sales-force efficiency |
| Contribution margin |
Shows whether volume covers commercial costs |
| Cash burn |
Determines financing needs |
| Net debt and equity dilution |
Affect shareholder economics |
| European royalties |
Provide lower-cost supplemental revenue |
The base commercial thesis is continued U.S. growth followed by a transition toward operating leverage. The downside thesis is that payer restrictions and generic substitution force Shield to spend heavily to defend a product with limited pricing power. The upside thesis is that ferric maltol becomes a recognized second-line oral therapy before intravenous treatment, expanding the market beyond a niche intolerance population.
Key Takeaways
- Accruer is an oral ferric maltol product approved by the FDA in July 2021.
- Shield Therapeutics controls the U.S. commercial opportunity; Norgine markets Feraccru in Europe.
- Reported Shield revenue rose from approximately $21.7 million in 2022 to approximately $65.6 million in 2023. [2,3]
- The largest commercial competitors are generic ferrous salts and intravenous iron products.
- Accruer has no biosimilar risk because ferric maltol is a small molecule.
- U.S. five-year NCE exclusivity is tied to the 2021 approval and expires in 2026.
- Generic-entry timing depends on Orange Book patents, Paragraph IV litigation, settlements, and approval timing.
- The commercial opportunity is strongest among adults who fail or cannot tolerate conventional oral iron.
- The central investment question is whether prescription growth can produce operating leverage before generic or therapeutic substitution pressure intensifies.
FAQs
Does Accruer require prior authorization?
Coverage varies by payer. Many plans may apply step therapy requiring use of generic oral iron before approving Accruer.
Is Accruer safer than ferrous sulfate?
Accruer is positioned around improved gastrointestinal tolerability, but treatment selection depends on patient characteristics, indication, iron deficit, and clinical response.
Can Accruer replace intravenous iron?
Usually not for patients requiring rapid or substantial iron repletion. Its commercial role is primarily as an oral option before or instead of intravenous therapy in selected adults.
Is ferric maltol approved for children?
The U.S. Accruer approval is for adults. Pediatric use is not covered by the adult FDA indication.
What would most increase Accruer’s valuation?
The most important value drivers are sustained U.S. prescription growth, improved payer coverage, lower customer-acquisition costs, positive operating cash flow, and a clear period of post-2026 patent protection.
References
- U.S. Food and Drug Administration. (2021). Accrufer (ferric maltol) prescribing information.
- Shield Therapeutics plc. (2023). Annual report and accounts 2022.
- Shield Therapeutics plc. (2024). Annual report and accounts 2023.
- U.S. Food and Drug Administration. (2024). Small molecule drug products approved under the Hatch-Waxman amendments.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- Norgine B.V. (2023). Feraccru product information and commercial materials.
